Document is current
Any future updates will be listed below
-
Authors
Vitale, Silvia R.
Helmijr, Jean A.
Gerritsen, Marjolein
Coban, Hicret
van Dessel, Lisanne F.
Beije, Nick
van der Vlugt-Daane, Michelle
Vigneri, Paolo
Sieuwerts, Anieta M.
Dits, Natasja
van Royen, Martin E.
Jenster, Guido
Sleijfer, Stefan
Lolkema, Martijn
Martens, John W. M.
Jansen, Maurice P. H. M. http://orcid.org/0000-0003-1258-9804
-
Funding
Funding for this research was provided by:
KWF Kankerbestrijding (EMCR2014-6340)
Cancer Genomics Centre
- License Information
-
More Information
Article History
Received: 27 October 2020
Accepted: 3 March 2021
First Online: 24 March 2021
Declarations
:
: The study was approved by the institutional review board of the Erasmus MC Medical Ethical Committee (Erasmus MC ID: MEC-15-616) and conducted in accordance with the Declaration of Helsinki and applicable regulatory requirements. The study was carried out according the REMARK guidelines and Code of Conduct of the Federation of Medical Scientific Societies in the Netherlands (ExternalRef removed). All patients provided written informed consent before blood collection and data analysis.
: Not applicable.
: None of the authors has a conflict of Interest, except Professor Guido Jenster (Erasmus MC) who has a license agreement with Cell Guidance Systems for the CD9-EV TRIFic exosome assay (Cat. No: EX101).
